GLPwatch
Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).
Aust Prescr · 2025
Last updated 2026-08-28| Journal | Aust Prescr, 2025 |
|---|---|
| Citations | 1 |
| Molecules | semaglutide |
Full record and abstract on PubMed 40568689 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.